Premium
Anaplastic ganglioglioma—A diagnosis comprising several distinct tumour types
Author(s) -
Reinhardt Annekathrin,
Pfister Kristin,
Schrimpf Daniel,
Stichel Damian,
Sahm Felix,
Reuss David E.,
Capper David,
Wefers Annika K.,
Ebrahimi Azadeh,
Sill Martin,
Felsberg Joerg,
Reifenberger Guido,
Becker Albert,
Prinz Marco,
Staszewski Ori,
Hartmann Christian,
Schittenhelm Jens,
Gramatzki Dorothee,
Weller Michael,
Olar Adriana,
Rushing Elisabeth Jane,
Bergmann Markus,
Farrell Michael A.,
Blümcke Ingmar,
Coras Roland,
Beckervordersandforth Jan,
Kim Se Hoon,
Rogerio Fabio,
Dimova Petia S.,
Niehusmann Pitt,
Unterberg Andreas,
Platten Michael,
Pfister Stefan M.,
Wick Wolfgang,
HeroldMende Christel,
Deimling Andreas
Publication year - 2022
Publication title -
neuropathology and applied neurobiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.538
H-Index - 95
eISSN - 1365-2990
pISSN - 0305-1846
DOI - 10.1111/nan.12847
Subject(s) - ganglioglioma , pleomorphic xanthoastrocytoma , anaplastic astrocytoma , pathology , pilocytic astrocytoma , glioma , astrocytoma , idh1 , oligodendroglioma , biology , medicine , epilepsy , cancer research , mutant , biochemistry , gene , neuroscience
Aims Anaplastic ganglioglioma is a rare tumour, and diagnosis has been based on histological criteria. The 5th edition of the World Health Organization Classification of Tumours of the Central Nervous System (CNS WHO) does not list anaplastic ganglioglioma as a distinct diagnosis due to lack of molecular data in previous publications. We retrospectively compiled a cohort of 54 histologically diagnosed anaplastic gangliogliomas to explore whether the molecular profiles of these tumours represent a separate type or resolve into other entities. Methods Samples were subjected to histological review, desoxyribonucleic acid (DNA) methylation profiling and next‐generation sequencing. Morphological and molecular data were summarised to an integrated diagnosis. Results The majority of tumours designated as anaplastic gangliogliomas resolved into other CNS WHO diagnoses, most commonly pleomorphic xanthoastrocytoma (16/54), glioblastoma, isocitrate dehydrogenase protein (IDH) wild type and diffuse paediatric‐type high‐grade glioma, H3 wild type and IDH wild type (11 and 2/54), followed by low‐grade glial or glioneuronal tumours including pilocytic astrocytoma, dysembryoplastic neuroepithelial tumour and diffuse leptomeningeal glioneuronal tumour (5/54), IDH mutant astrocytoma (4/54) and others (6/54). A subset of tumours (10/54) was not assignable to a CNS WHO diagnosis, and common molecular profiles pointing to a separate entity were not evident. Conclusions In summary, we show that tumours histologically diagnosed as anaplastic ganglioglioma comprise a wide spectrum of CNS WHO tumour types with different prognostic and therapeutic implications. We therefore suggest assigning this designation with caution and recommend comprehensive molecular workup.